The year in cardiovascular medicine 2021: cardio-oncology

• Published in: European heart journal Vol. 43; no. 9; pp. 857 - 862
• Main Authors: Herrmann, Joerg, López-Fernández, Teresa, Lyon, Alexander R.
• Format: Journal Article
• Language: English
• Published: Oxford University Press 01.03.2022
• Subjects: Cardio-oncology; Cardiovascular diseases; Cancer
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/ehab891

Graphical Abstract Graphical Abstract Key studies in cardio-oncology in 2020–21, by main topic areas (columns) and clinical vs. basic research (rows). Left panel, Top: Frequency and survival prognosis of the four severity strata of cardiotoxicity (none, mild, moderate, and severe), from Lopez-Sendon J, et al.12 Middle: Illustration of the main findings of the SUCCOUR trial on early, global longitudinal strain imaging-based recognition and treatment of anthracycline cardiotoxicity, from Thavendiranathan et al. (with permission from Elsevier, Inc.).38 Bottom: Outline of the experimental and translational finding of anti-PD1 immune checkpoint inhibitor therapy-related cardiac function decline, from Michel et al.44 Middle panel, Top: Illustration of the increased risk of arterial and venous thromboembolism in cancer compared with the general population, from Grilz et al.14 Middle: Cumulative incidence of myocardial infarction (MI) in cancer and non-cancer patients after percutaneous coronary intervention (PCI) in the first year and thereafter; the dual anti-platelet therapy (DAPT) score stratifies early and late risk in both groups, from Guo et al. (with permission from Elsevier, Inc.).16 Bottom: Outline of key experimental findings of T-cell driven pro-atherosclerotic effects of immune checkpoint inhibtor therapy, from Poels et al. (permission under a Creative Commons license).46 Right panel: Number of reports on drug-induced QT prolongation, ventricular arrhythmias, and Torsades de Pointes in the World Health Organization pharmacovigilance database from the 60s to the current era, from Salem et al.18 Middle: Incidence of new-onset atrial fibrillation after breast cancer diagnosis, from Guha et al.24 Bottom: Outline of the molecular targets and mechanisms of ibrutinib-related atrial fibrillation, from Awan FT et al. (with permission from Wolters Kluwer Health, LWW).21